Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.46K$15.46Kderived+26.6% vs Q4 2016 Net Income-$1.44M-$1.44MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$14,660N/M Operating Incomederived-$1,050,465N/M Operating Cash Flowderived-$1,015,664N/M Margins · derivedGross margin94.8%+921.5 pt vs Q4 2016
Operating margin-6796.0%−489.4 pt vs Q4 2016
Net margin-9300.7%+390.6 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 15, 2018 · 74 d after period end